
The INSPIRES trial assessed the efficacy and safety of clopidogrel-aspirin vs aspirin alone in ischemic stroke patients, stratified by glycemic status. Clopidogrel-aspirin reduced recurrent stroke in patients without type 2 diabetes and those with newly diagnosed type 2 diabetes, but not in those with a history of type 2 diabetes. The bleeding risk did not differ by treatment in any subgroup. The results suggest that patients without or with newly diagnosed diabetes benefit more from clopidogrel-aspirin.
Like
Save
Share